each 100 ml Contains :
• Active Ingredients 
Desloratadine                                                           50mg
• Inactive Ingredients 
Carboxy methyl cellulose sodium                              0.3 mg
Sorbitol soln. 70%                                                   20 mg
Glycerin                                                                 10.0 gm
Sodium benzoate                                                     0.3 gm
Aspartame                                                              0.3 mg
Citric acid                                                               2.5 mg  
Orange flavor oil                                                      0.5 gm
FD & C yellow                                                         60.01 gm
Purified water to                                                      100 ml

Syrup

Desloratadine is a long-acting tricyclic histamine antagonist with selective H1-receptor histamine antagonist activity. Receptor binding data indicates that a concentration of 2-3 nanogram/ml . Desloratadine shows significant interaction with the human histamine H1-receptor. Desloratadine inhibited histamine release from mast cell in vitro.
Results of tissue distribution study showed that desloratadine did not readily cross the blood brain barrier..

- Absorption : neither food nor grapefruit juice has an effect on the bioavailability of desloratadine.
- Distribution : Desloratadine and 3-hydroxydesloratadine are approximately 82% to 87% to 89% bound to plasma proteins, respectively. Protein binding of desloratadine and 3-hydroxydesloratadine was unaltered in subjects with impaired renal function .
- Metabolism : desloratadiene is extensively metabolized to 3-hydroxydesloratadine ,an active metabolite,which is subsequently glucuronidated. No overall differences in safety where observed between poor metabolizer and normal metabolizers.
- Elimination : the mean elimination half life of desloratadine was 27 hours. the degree of accumulation after 14 days of dosing was consistent with half life & dosing frequency.

- Seasonal Allergic Rhinitis: LORAFAST  is indicated for the relief of the nasal & non-nasal symptoms of seasonal rhinitis (in patients 2 years of age & older).
- Perennial Allergic Rhinitis: LORAFAST  is indicated for the relief of the nasal & non-nasal symptoms of perennial allergic rhinitis (in patients 6 months of age & older).
- Chronic Idiopathic Urticaria: LORAFAST  is indicated for the symptomatic relief of pruritus, reduction in the number of hives & size of hives in patients with chronic idiopathic urticaria (6 months of age & older).

- Adults & children 12 years of age &over: the recommended dose of LORAFAST is 2 teaspoonfull ONCE daily.
- Children 6 to 11 years of age: the recommended dose of LORAFAST is 1 teaspoonfull ONCE daily.
- Children 12 months to 5 years of age: the recommended dose of LORAFAST is ½ teaspoonfull ONCE daily.
- Children 6 to 11 months of age: the recommended dose of LORAFAST is 2 ml ONCE daily. should be administered with a commercially available measuring dropper or syringe that is calibrated to deliver 2 ml.

LORAFAST is contraindicated in patients who are hypersensitive to this medication or to any of it’s ingredients or to loratadine.

The following spontaneous adverse events have been reported during the marketing of desloratadine: tachycardia ,palpitations and rarely hypersensitivity reactions ( such as rash ,pruritus, urticaria , edema, dyspnea and anaphylaxis) and elevated liver enzymes including bilirubin and very rarely hepatitis , allergic rhinitis and chronic idiopathic urticaria.

Disloratidine  exhibits an antihistaminic effect by 1 hour. 

- Pregnancy category C: desloratadine should not be used during pregnancy, and only used if clearly needed.
- Nursing mothers: Desloratadine passes into breast milk, therefore a decision should be made whether to discontinue nursing or to discontinue Desloratadine taking according to the importance of drug to the mother.

LORAFAST contains  Desloratadine;
• Carcinogenesis, mutagenesis,Impairment of fertility:
- The studies did not show significant  increase in the incidence of any tumor.
- In genotoxicity studies there was no evidence of genotoxic potential in a reverse mutation assay.
-there was no effect on female fertility in rats at Desloratadine dose up to 24 mg/ml , and there was also no effect on male fertility in rats in dose up to 3 mg/ml.
• Pediatric Use: The safety & effectiveness of LORAFAST has not been demonstrated in pediatric patients less than 6 month of age.
• Geriatric Use: In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
• Sorbitol precaution: Not to be used for diabetic patients.

There is no information to indicate that abuse or dependency occur with LORAFAST.

In the event of overdoses, consider standard measures to remove any unabsorbed drug. Symptomatic & supportive treatment is recommended. Desloratadine and it’s metabolite are not eliminated by heamodialysis.

A bottle contains 100 ml.

Store below 30?c ,protected from light and
keep out of the reach of children.